Zinzino announced its preliminary sales results for 2025. Group revenue increased 46% in the fourth quarter, reaching $113 million, and contributing to a full year 2025 revenue increase of 51%, when compared to 2024.

Oriflame announced its recapitalization transaction was successfully executed. With this completed, the company now has the opportunity to restructure is debt and capital structure. New financing terms, which include updated loan and bond arrangements, will now be in place, which Oriflame believes will strengthen its balance sheet and support its long-term operations.

Oriflame announced that it has successfully obtained the necessary number of bondholder consents to approve amendments to its outstanding debt as part of its recapitalization plan.

Shaklee reported one of its strongest periods of growth in its 70-year history. The company described this momentum as “record-breaking growth” and reported an average increase of 29% year-over-year improvement in US and Canada for the month of November.

Bravenly Global announced that November 2025 was its largest revenue month to date. This revenue milestone reflects the company’s consistent pattern of growth, which was reported at +3,009% across the last three years by the Inc. 5000.

Zinzino reported its preliminary sales results for November 2025. Zinzino group revenue grew 45% overall year-over-year. Zinzino sales markets grew 49% year-over-year, reaching $39 million, while Faun Pharma’s external sales experienced decline. Accumulated revenue from January 2025 to November 2025 increased by 54% year-over-year to $320 million. The Asia-Pacific market, which includes Australia, New Zealand, […]